Loading…
← CockpitCompetitor Analysis › 3046.T JINS HOLDINGS Inc.Open in the cockpit ↗

JINS HOLDINGS Inc.3046.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties
Momentum neutral 59
Mkt cap
$963M
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$8.29M
20-day average traded
Fwd P/E
18.7×
forward earnings
ROIC−WACC
+20.1 pp
WACC 5.0%
Hurdle
-18 pp
Req g minus delivered
Next earnings
51 days
8 Jan 2027
Close · JPY¥6,550
1D-2.2%
1W-4.8%
1M+9.2%
3M-0.8%
6M-7.9%
YTD+18.4%
1Y-12.0%
ATR %3.8%
52w lowhigh30.0% off high

What JINS does

No business profile yet.

JINS at a glance

Size JINS (3046.T) is a Japan Health Care company (Medical Specialties) with a market value of $963M, the 757th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥6,550 on 18 Nov 2026.

Performance Over six months the shares fell 7.9%, against -11.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 14.4% over the last twelve months (peer median +10.0%); the operating margin is 10.3% (peer median 9.6%).

Valuation It trades at 18.7× forward earnings against a peer median of 20.9× (6th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 20.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 8 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20263046.T 90Peer median 88
Six months, rebased to 100: JINS against the median of its 20 peers (local-currency closes).

JINS financials

Reported figures in JPY; fiscal year ends 2026-08-31. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue¥111B¥111B¥97.2B¥83.0B¥73.3B
Revenue growth—+14%+17%+13%—
Gross profit¥85.8B¥83.0B¥72.9B¥61.5B¥53.3B
EBITDA¥15.6B¥15.6B¥15.0B¥10.8B¥7.76B
Net income¥7.80B¥7.80B¥8.33B¥4.67B¥1.76B
Free cash flown/a¥7.95B¥8.53B¥9.10B¥3.14B
Capital expendituren/a¥7.86B¥5.44B¥2.62B¥3.59B
Total debt¥5.71B¥5.71B¥8.99B¥14.1B¥13.5B

Quarterly statements and history in the cockpit →

JINS competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%7730SFL7780290650300143CBLL3002063006856523KURNAORT301021600055EUZCSTLBVS301580688575IRMD3046.T6-month return →1-month return →
Up and to the right = strong over both horizons. JINS is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×7730SFL77803001433002066523KURNAORT301580688575IRMD6887673046.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JINS is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%7730SFL2906503001433002066523301021EUZCSTL301580688575IRMD3046.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. JINS is the large dot.

JINS competitors and peer comparison

How JINS compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JINS against its 20 peers (data as of 18 Nov 2026)
Measure3046.TPeer medianRank in peer set
1-month return+9.2%-6.0%3rd highest of 21
6-month return-7.9%-11.7%9th highest of 21
Distance from 52-week high-30.0%-29.5%11th highest of 21
Revenue growth (TTM)+14.4%+10.0%7th highest of 21
Operating margin10.3%9.6%10th highest of 21
Forward P/E18.7×20.9×6th cheapest of 16
Growth the price implies (Req g, 7 yrs)-6.1%7.6%least demanding of 15
Growth delivered (Del g)+11.7%+12.4%6th lowest of 15
Hurdle (Req g minus delivered)-17.8 pp-3.7 ppleast demanding of 15
ROIC minus cost of capital+20.1 pp+2.8 pp3rd highest of 20
EV / EBITDA9.5×10.8×5th cheapest of 11
Net debt / EBITDA-0.4×0.3×4th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a

Questions

Which companies are JINS's closest peers?
The cockpit's peer set: Mani (7730.T), Safilo (SFL.MI), Menicon (7780.T), L&C BIO (290650.KS), INKON Life Technology (300143.SZ), Ceribell (CBLL), Edan Instruments (300206.SZ), Amoy Diagnostics (300685.SZ).
Is JINS expensive compared with its peers?
On forward p/e it trades at 18.7× against a peer median of 20.9×, 6th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has JINS stock performed?
Over six months to 18 Nov 2026 the shares returned -7.9% against -11.7% for the median peer; over one year -12.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.